Evidence map›Paper›PMID 29956762›Full record

ArticleMolecular medicine reports2018

Recombinant club cell protein 16 (CC16) ameliorates cigarette smoke‑induced lung inflammation in a murine disease model of COPD.

Min Pang, Hong-Yan Liu, Ting Li, Dan Wang, Xiao-Yun Hu, Xin-Ri Zhang, Bao-Feng Yu, Rui Guo, Hai-Long Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Club cell secretory protein and lung function in children with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Article
  11. Article
  12. LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia.Cellular and molecular life sciences : CMLS · 2021
    Article
  13. Article
  14. Very Late Antigen-4: A Novel Receptor for Club Cell Secretory Protein 16 to Control Inflammation.American journal of respiratory and critical care medicine · 2021
    Article
  15. Article
  16. Article
  17. Club Cell Protein 16 Attenuates CD16Journal of immunology research · 2021
    Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Min PangDepartment of Respiratory Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Hong-Yan LiuSchool of Basic Medicine; Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Ting LiDepartment of Respiratory Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Dan WangDepartment of Respiratory Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xiao-Yun HuDepartment of Respiratory Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xin-Ri ZhangDepartment of Respiratory Medicine, The First Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Bao-Feng YuSchool of Basic Medicine; Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Rui GuoSchool of Basic Medicine; Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Hai-Long WangSchool of Basic Medicine; Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Shanxi Medical University · CNFirst Hospital of Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Club cell protein (CC16) is expressed primarily by club cells possesses anti‑inflammatory properties and is located in the bronchiolar epithelium. Previous studies have demonstrated that CC16 deficiency is associated with the progression of chronic obstructive pulmonary disease (COPD). In the present study, the therapeutic effects of recombinant rat CC16 protein in mice with COPD were examined and the underlying mechanisms investigated. A total of 30 adult male C57/BL6 mice were randomly divided into three groups (10 mice/group). A mouse COPD model was generated by exposing 20 mice to cigarette smoke (CS) for 24 weeks. A total of 10 mice were treated intranasally with rCC16 (2.5 µg/g body weight) and control mice were exposed to normal room air. Results indicated that rCC16 treatment ameliorated pathological damage in the lungs and reduced the production of tumor necrosis factor (TNF)‑α, interleukin (IL)‑6 and IL‑8, which were induced by CS exposure. After rCC16 administration, endogenous CC16 was upregulated and the body weight of COPD mice was increased, whereas the opposite was observed in CS‑exposed mice. Additionally, rCC16 treatment inhibited the DNA binding of NF‑κB/p65 in lung tissues and reduced nuclear translocation of NF‑κB/p65 in BALF and epithelial cells. Moreover, rCC16 treatment lead to a decrease in the total number of BALF cells, including macrophages, which was elevated in COPD mice. In conclusion, the present results demonstrate that rCC16 has therapeutic effects on COPD by downregulating pro‑inflammatory factors via the NF‑κB pathway.

Indexed as

AnimalsCigarette SmokingCytokinesDisease Models, AnimalInflammationMaleMicePneumoniaPulmonary Disease, Chronic ObstructiveRecombinant ProteinsRespiratory MucosaSignal TransductionTranscription Factor RelAUteroglobinCytokinesRecombinant ProteinsRela protein, mouseScgb1a1 protein, mouseTranscription Factor RelAUteroglobin

Identifiers

PMID29956762
PMCPMC6072201
OpenAlexW2811466415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.